June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Patients with Dry Eye Disease and Depression: A Potential Role for VAL66MET Single Nucleotide Polymorphism on Treatment Response
Author Affiliations & Notes
  • Joelle Hallak
    Ophthalmology & Visual Sciences, Illinois Eye & Ear Infirmary, Chicago, Illinois, United States
  • X. Raymond Gao
    Ophthalmology & Visual Sciences, Illinois Eye & Ear Infirmary, Chicago, Illinois, United States
  • Sandeep Jain
    Ophthalmology & Visual Sciences, Illinois Eye & Ear Infirmary, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Joelle Hallak, None; X. Raymond Gao, None; Sandeep Jain, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2683. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Joelle Hallak, X. Raymond Gao, Sandeep Jain; Patients with Dry Eye Disease and Depression: A Potential Role for VAL66MET Single Nucleotide Polymorphism on Treatment Response. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2683.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the role of Val66Met Single Nucleotide Polymorphism (SNP) in symptom change of dry eye disease (DED) patients following treatment.

Methods : Thirty-six patients were followed-up for a minimum of 6 months for treatment efficacy and symptom response. Saliva for SNP analysis was collected at baseline. Patients were asked to rate their symptoms on a scale of 0 to 4. Additionally, during each follow-up, patients were asked about their symptom experience as follows: no change; 25% better; 50% better; 75% better; or worse. Prescribed DED treatments for each patient were also collected, and scored as either 1 point or 2 points based on aggressiveness. The last follow-up time for each patient was selected for analysis. Mean and median baseline scores and follow-up scores were generated and compared for each patient using a paired t-test. DED treatment and change in symptom score were stratified by genotype.

Results : Mean age was 53 years + 15.7. Forty-two percent were clinically diagnosed with depression. The genotype distribution for Val66Met was 0.1% for AA, 30.6% for GA, and 63.9% for GG. The average mean follow-up of those patients was 15.52 + 8.4 months and the median follow-up was 20.3 months. Patients with GG genotype showed significant decreases in dryness and pain symptoms between baseline and the last follow-up time point (dryness: 3.0 to 1.7, P=0.005; pain: 2.2 to 0.5, P=0.002) whereas patients with the GA genotype did not exhibit significant decreases in the dryness and pain symptoms (2.5 till 2.0 P=0.4 for dryness; 1.5 to 0.4 P=0.1 for pain). Thirty one percent of patients with the GG genotype said that their symptoms improved by 25%, 46.2% reported no change in symptoms, and 23.1% reported that their symptoms became worse. As for patients with the GA genotype, 25.0% said that their symptoms improved by 25%, 62.5% reported no change in symptoms, and 12.5% reported that their symptoms became worse (P=0.90). Additionally, 62.5% of DED patients with the GA genotype were clinically diagnosed with depression, compared to 30.8% of DED patients with the GG genotype. As for prescribed treatments, the mean level of aggressiveness between GG and GA genotype did not differ clinically nor statistically (2.7 and 2.8, respectively, P=0.8).

Conclusions : This study suggests that Val66Met SNP in the BDNF gene may regulate the efficacy of DED treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×